WHO designates Shan5 prequalified

The World Health Organization extends "prequalification status" to Sanofi's (SNY +0.6%) Shan5 vaccine. This allows United Nations agencies like UNICEF to purchase the product.

Sanofi developed Shan5 with the Indian biotech firm Shantha. It was cleared for sale in that country in March.

The vaccine protects children from diptheria, tetanus, pertussis, Hib and hep B.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs